[ad_1]
February 24, 2019
<img src = "https://media.pulmonologyadvisor.com/images/2019/02/24/peanutsboiledg957193828resi_1530970.jpg?format=jpg&zoom=1&quality=70&anchor=middlecenter&width=320&mode=pad" alt "favorable security profile with symptoms Gastrointestinal badociated with <2% of doses. "title =" The oral boiled peanut immunotherapy had a favorable safety profile, with gastrointestinal symptoms badociated with <2% of doses." border="0"/>
Oral immunotherapy with boiled peanut had a favorable safety profile with gastrointestinal symptoms badociated with
SAN FRANCISCO – Oral immunotherapy to boiled peanut induces sustained insensitivity in peanut-allergic children, according to the findings of the American Academy of Allergy's annual meeting, Asthma & Immunology, held Feb. 22-25 at San Francisco.
In this randomized controlled trial of phase 2B / 3 (oral immunotherapy with boiled peanut for the treatment of peanut allergy – BOITI; ID: ClinicalTrials.gov: NCT02149719), researchers sought to determine the effectiveness and safety of oral immunotherapy to boiled peanut.
A total of 47 children (8-17 years old) with confirmed peanut allergy using a double-blind, placebo-controlled food trial were randomized to 2: 1 for oral boiled peanut immunotherapy or standard therapy (avoidance). Oral immunotherapy was modified with boiled peanuts for about 6 months, and then was followed by maintenance with grilled peanut. At 12 months, children had to face repeated nutritional problems to evaluate the response, oral immunotherapy to peanut was discontinued and the lack of sustained response was badessed after 4 weeks.
Before oral immunotherapy, the median cumulative elimination dose was 143 mg of peanut protein in these children. Of the 32 participants badigned to active treatment, 24 presented the main result of desensitization to 1.4 g of peanut protein (P <.0001) and of those, 14 tolerated >4.4 g of peanut protein. Sustained reactivity after 4 weeks occurred in 13 participants.
Anaphylaxis occurred in 9 patients (17 episodes in total), but overall, oral immunotherapy to boiled peanut exhibited a favorable safety profile, with gastrointestinal symptoms. less than 2% of doses.
The researchers planned a head-to-head comparison of oral immunotherapy with roasted and roasted peanut in a wider cohort in order to get a better idea of the efficacy and safety of these two modalities.
Reference
N Patel, Vazquez-Ortiz M, Robb A, Shamji MH, Campbell DE, Turner PJ. Successful desensitization and lack of sustained response with modified peanut: results of the BOPI study. Presented at: 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology; February 22-25, 2019; San Francisco, CA. Summary 252.
[ad_2]
Source link
